1/30
08:03 am
mnov
MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
Low
Report
MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
1/30
02:52 am
mnov
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients [Yahoo! Finance]
Medium
Report
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients [Yahoo! Finance]
1/29
06:00 pm
mnov
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients
Low
Report
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients
1/7
07:11 am
mnov
MediciNova (NASDAQ:MNOV) was upgraded by analysts at Lucid Cap Mkts to a "strong-buy" rating.
Low
Report
MediciNova (NASDAQ:MNOV) was upgraded by analysts at Lucid Cap Mkts to a "strong-buy" rating.
1/6
09:00 am
mnov
2026 New Year’s Greetings from the CEO
Low
Report
2026 New Year’s Greetings from the CEO
12/18
08:05 am
mnov
MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
Low
Report
MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
12/18
06:46 am
mnov
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy [Yahoo! Finance]
Low
Report
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy [Yahoo! Finance]
12/18
06:00 am
mnov
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
Low
Report
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
12/8
11:41 am
mnov
MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
Neutral
Report
MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
12/8
06:00 am
mnov
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
Medium
Report
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
12/1
06:00 pm
mnov
Message from the CEO to MediciNova Shareholders
Low
Report
Message from the CEO to MediciNova Shareholders
11/25
01:54 pm
mnov
MediciNova (NASDAQ:MNOV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
MediciNova (NASDAQ:MNOV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/18
06:57 am
mnov
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor [Yahoo! Finance]
Neutral
Report
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor [Yahoo! Finance]
11/18
06:00 am
mnov
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
Low
Report
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor